Navigation Links
ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Date:1/29/2008

for the upcoming IND submission.

- Prepared to file a Phase I IND application and begin human clinical

trials for the CD44 Cancer Stem Cell program in 2008.

Trop-2 Signal Transduction Program

- Announced positive findings demonstrating a significant anti-tumor

effect of the lead anti-Trop-2 antibody in animal models of human

pancreatic cancer, inhibiting tumor growth by up to 100 percent.

- Discovered that ARIUS' Trop-2 antibody inhibits a key growth

regulatory pathway in cancer cells.

- Trop-2 therapeutic antibody program was selected for presentation and

press conference at the AACR-NCI-EORTC 2007 International Conference

on Molecular Targets and Cancer Therapeutics. The abstract was one of

only 12 selected from more than 900 abstracts for presentation.

- Engaged the manufacturer Laureate Pharma Inc. for the cGMP

manufacture of humanized AR47A6.4.2 for Phase 1 clinical supply. Cell

line producing the humanized anti-Trop-2 antibody was successfully

transferred to Laureate.

- Preparing to complete the dose ranging toxicology studies in the

first quarter of 2008, followed by a pre-IND meeting with the FDA in

the third quarter of 2008, and the filing of a Phase I IND

application in late 2008.

CD59 Complement Inhibitor Program

- Announced positive findings demonstrating highly potent tumor

regression in animal models of breast cancer at doses as low as

0.2 mg/kg.

- Selected to discuss results of the CD59 therapeutic antibody program

at the AACR-NCI-EORTC 2007 International Conference on Molecular

Targets and Cancer Therapeutics press conference.

- Cell line producing humanized CD59 antibody was generated

successfully; humanized mAb retains binding characteristics and

potent in vivo activity.

<
'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... 23, 2014 The report ... as its definition, classification, application and industry ... manufacturing process, and product cost structure. Production ... The analysis also covers upstream raw materials, ... development trend and proposals. In the end, ...
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... All amounts are in US dollarsQUEBEC CITY, March ... AEZS ; TSX: AEZ), a global biopharmaceutical ... announced the signing of a development, commercialization and ... SNY ) for the development, registration and ...
... as buckyballs may be able to keep the nation,s ... prevent arteries from clogging up. , Engineers at Duke ... bacteria and other microorganisms to accumulate on the membranes ... leads the researchers to believe that coating pipes and ...
... OMAHA, Neb., March 5 Transgenomic, Inc. (OTC ... announced today its Molecular Laboratory has received notification ... offering its services in the state. Transgenomic ... including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology ...
Cached Biology Technology:AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 5Buckyballs could keep water systems flowing 2Buckyballs could keep water systems flowing 3Transgenomic Awarded Clinical Laboratory Certification in California 2Transgenomic Awarded Clinical Laboratory Certification in California 3
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... German . Aggressive male mating behavior might ... it can drive the species to extinction, an international research ... of Zurich has demonstrated in a mathematical model. ... of the individual is able to influence processes on a ...
... Most degenerative diseases begin with a gradual loss ... For example, in type I diabetes, hyperglycemia commonly develops when ... are lost; in Parkinson,s disease, motor dysfunction typically begins when ... by 70 to 80 percent. Finding ways to stop early ...
... Computer games are not just for kids. New research published ... Central open access journal, shows that computer games can speed ... stroke. It is often difficult for stroke victims to ... have problems six months later. Scientists in America looked at ...
Cached Biology News:Aggressive male mating behavior can endanger species 2New mouse model may lead to new therapies for degenerative diseases 2
Recombinant Mouse IL-23, CF...
... ActivePro In Vitro Translation ... E.coli lysate, synthesizes higher ... well as proteins with ... competing kits. This results ...
... , Customer Peptide Synthesis , Containing one Phospho-Amino ... mg will be returned to customer conjugation of peptide to KLH ... Maintenance 102 days/each , Pre-immune bleed ... , Test bleed (app. 5 ml) x1 ...
Donor Goat Serum...
Biology Products: